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Abstract
The recent advance in identifying risk genes has provided an unprecedented opportunity for 
developing animal models for psychiatric disease research with the goal of attaining translational 
utility to ultimately develop novel treatments. However, at this early stage, successful translation 
has yet to be achieved. Here, we review recent advances in modeling psychiatric disease, discuss 
utility and limitations of animal models, and emphasize the importance of shifting from behavioral 
analysis to identifying neurophysiological defects, which are likely more conserved across species 
and thus increase translatability. Looking forward, we envision that preclinical research will align 
with clinical research to build a common framework of comparable neurobiological abnormalities 
and form subgroups of patients based on similar pathophysiology. Experimental neuroscience can 
then use animal models to discover mechanisms underlying distinct abnormalities and develop 
strategies for effective treatments.
Introduction
According to the latest NIMH estimates from 2006, more than three times as many people in 
the United States paid expenses for care related to psychiatric disorders as compared to those 
requiring cancer treatments (cost statistics on http://nimh.nih.gov). Strikingly, most of the 
drug treatments these patients receive were discovered serendipitously decades ago and are 
often unspecific and ineffective. The current outlook for developing novel compounds is also 
bleak given consistently lower clinical approval success rates of CNS compounds compared 
to their non-CNS counterparts (Figure 1), and the lack of mechanistic understanding that 
indicates no clear path to success. Consequently, pharmaceutical companies drastically 
reduced R&D expenditures into psychiatric disorders. This is in stark contrast to a 
comparatively growing number of treatments that are being developed and approved in the 
US for other non-CNS diseases with increasingly understood pathophysiological 
mechanisms, such as neoplastic diseases (Figure 1).
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To set the stage for a similar development in psychiatric disease research, we must gain a 
better understanding of the pathophysiology of these disorders, including improving our 
understanding of the heterogeneity of the disorders. First, we must advance our knowledge 
regarding disease etiology. Since most psychiatric disorders are highly heritable, identifying 
genetic factors conveying risk is a crucial step. Current large-scale genetic studies are 
already taking this step by discovering numerous risk genes for various psychiatric 
diseases1–5. Second, due to the lack of access to diseased brain tissues, we must use model 
systems to investigate neurophysiological abnormalities that may be caused by genetic 
variants and mutations. While no model systems will ever perfectly phenocopy human 
disease, we can use cellular models for the interrogation of conserved molecular pathways or 
animal models to dissect complex neural circuit defects that may underlie particular 
phenotypic abnormalities found in patients. Third, beyond the assessment of observable 
signs in affected individuals, we need to identify clusters of affected individuals with similar 
neurophysiological abnormalities that have been molecularly understood and targeted for 
treatment development in model systems. Eventually, we will be able to give these more 
homogenous clusters of patients interventions developed for their specific 
pathophysiological mechanism (personalized medicine).
The past decade has seen a large increase in the number of rodent models generated for 
mechanistic research and treatment development. However, many of the early studies using 
these models have focused on behavioral characterizations. Only recently, animal model 
studies are starting to reveal mutation-specific neural circuit defects that might be relevant to 
disease pathology (see review in6,7). The lack of deep understanding of disease-relevant 
cellular and circuit mechanisms is a bottleneck for successful translation in psychiatry 
research.
In this perspective, we discuss the utility and limitations of animal models. We emphasize 
the importance of using animal models that are based on disease etiology, the difficulties and 
approaches in modeling polygenic disorders, the necessity to shift emphasis from behavioral 
studies to neurophysiological characterization with a focus on translatable molecular and 
neural circuit mechanisms that are evolutionary conserved. Finally, we envision an 
integrated path forward that may enable us to better translate preclinical findings into 
effective treatments for psychiatric diseases.
Animal models and disease etiology
During the last decade, a host of animal models for psychiatric disease research have been 
developed. Generally, neuroscientists evaluate these models in terms of construct validity, 
face validity and predictive validity8,9. Construct validity in the context of animal models for 
psychiatric disease research refers to the degree to which the model is based on disease 
etiology, such as environmental or genetic risk conditions for developing the disease. An 
animal model’s face validity is its phenotypic resemblance to the human disease, while its 
predictive validity describes the similarities in treatment response between the animal model 
and human patients.
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Construct validity is impossible to achieve in an animal model if we do not understand the 
etiology. Little is known about etiology of psychiatric disease and no biomarkers are 
available except for a few syndromic disorders such as Rett syndrome and Fragile X 
syndrome where genetic lesions are known and used for diagnosis. Thus, clinicians assess 
patients based on phenotypic presentation and observable signs. For example, using 
guidelines of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5), a patient with impaired reciprocal social interactions combined with restricted, 
repetitive behaviors manifesting in early childhood would be diagnosed with autism 
spectrum disorder. Such heavily phenotype-based diagnoses in psychiatric diseases have 
inspired similar phenotypic assessment in animal models, particularly mice. For instance, 
comparison of the inbred mouse strain BTBR T+tf/J with the inbred mouse strain C57/BL6 
reveals that these mice show relatively less reciprocal social interaction, more grooming and 
different ultrasonic vocalizations10. Thus the BTBR mice have been proposed to be used as 
an autism model with high face validity and are used for ongoing preclinical drug 
testing11,12.
Similarly, it has been suggested that hyper-locomotion induced by Amphetamine, a 
psychostimulant that causes psychosis-like episodes in humans, is a predictively valid model 
for schizophrenia, given that treatment with approved antipsychotic drugs normalizes 
locomotion in these mice13. This hypothesis is supported by findings showing that 
schizophrenia is associated with increased amphetamine-induced synaptic dopamine 
concentrations14 and genetic association of the dopamine receptor DRD2 with 
schizophrenia4. At the same time, animal models centered on face and predictive validity 
have significant drawbacks. First, behaviors considerably diverged during the 80 million 
years since the last common ancestor of humans and mice, and should only be interpreted as 
a correlate of neural circuit function, and ideally only in models based on an evolutionarily 
proximal species. Second, approaches focused on predictive validity with the ultimate goal 
of discovering new therapeutic targets for the development of new compounds are inherently 
flawed, since they are biased towards the same molecular pathways that have been targeted 
in the past to limited success. Third, making inferences regarding human pathophysiology 
from these models is substantially complicated by the fact that they do not reflect the 
etiology of ASD or schizophrenia in human patients on the basis of current knowledge. An 
alternative approach is to deemphasize face and predictive validity and only consider them in 
models with high construct validity15.
How can we generate animal models that do not merely mirror phenotypic presentation, but 
are built on disease etiology? High heritability indicates that genetics is among the most 
important contributors to the development of psychiatric disease16,17.
In fact, it is widely assumed that genetic and environmental factors interact and converge on 
the same molecular pathways and, in combination, exert either protective or adverse 
effects17. In other words, the consequence of an environmental experience such as stress 
depends on the presence or absence of certain genetic variants within an individual. To date, 
reported environmental influences on psychiatric disease include (but are not limited to) 
maternal stress or infection during pregnancy, birth complications, infections, stressful life 
events, and drug abuse. While the field of modeling gene and environment interactions in 
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animals is still in its infancy and facing challenges related to uncertainties regarding nature 
and quantitative parameters of environmental factors, several studies have already shown 
promising results and excellent reviews on this exciting topic can be found elsewhere17–19. 
In the future, it may be crucial to explore and define standardized paradigms mimicking the 
exact time course and nature of gene-environment interplay in humans to determine to what 
extent, and how such interplay might affect developmental trajectories and neurophysiology.
The most significant advances in understanding etiology of psychiatric disorders in the past 
decade have come from genetic studies. Recent genome-wide association studies, copy 
number variation studies and whole exome sequencing studies have identified a large 
number of genetic risk factors for the development of psychiatric disease20 and references 
therein). Here, we outline how such genetic findings provide neuroscientists with the 
unprecedented opportunity to generate animal models that are similar in etiology to human 
disease and hence may prove to be more valid tools for the dissection of disease-associated 
pathways and circuits.
Utility and limitations of current animal models
A range of model organisms from fruit flies to zebrafish to mice15,21,22 has been 
successfully used to investigate gene to phenotype relationships and discover relevant 
molecular mechanisms underlying disease. Because the etiology and clinical expression of 
psychiatric disease is complex and related to the unique biology of humans, genetic findings 
will by no means enable researchers to generate animal models that recapitulate all 
phenotypic features of any one DSM-defined disorder. However, simpler units of 
intermediate disease phenotypes associated with genetic variants, called endophenotypes, 
are amenable to interrogation23,24. Compared to a disorder classified by a combination of 
complex symptoms, these quantifiable endophenotypes are thought to arise from the 
interaction of fewer gene products and can be neurophysiological, biochemical, 
neuroanatomical or behavioral. Using this approach, one hope in the field is deconstructing 
complex traits into fewer, distinct cellular and circuit mechanisms and subsequently 
reconstruct a general neurobiological logic, which will help explain and better predict 
consequences of similar genetic variants, acting singularly or in combination with non-
genetic factors.
Both common and rare genetic variants have been used to model gene-endophenotype 
relationships in animals. Here we define common variants as polymorphisms that occur in 
more than 5% of the human population. In animal models, such variants have been used to 
generate useful models that display endophenotypes, some of which have also been observed 
in humans25–27. The advantage of this approach is that investigators can study the relevance 
and endophenotypic impact of polymorphisms of interest in fairly large cohorts of human 
subjects and animal models in parallel using comparable experimental paradigms in both 
species25. While this approach has yet to be taken one step further to the demonstration of 
causality through circuit manipulation, the adoption of robust methodology and focus on 
comparable endophenotypes hold great promise for translation.
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Modeling neural circuit abnormalities in autism spectrum disorder
Currently, most animal disease modeling studies focus on highly penetrant rare mutations. 
Specifically, here we highlight genetic mouse models for interrogation of neural circuit 
abnormalities in autism spectrum disorders, a psychiatric disease where the discovery of 
highly penetrant variants in patients has enabled the study of monogenic models. Many such 
genetic models have been developed in the past decade, a few of which are shown in Table 
1.
These monogenic models have collectively revealed several cellular and neurophysiological 
abnormalities that may be related to autism pathology encompassing synaptic dysfunction 
and abnormal dendritic spine morphology, excitation-inhibition imbalance, and glia cell 
dysfunction. First, excitatory synaptic dysfunction in the hippocampus or the striatum is a 
consistent defect found in mutant mice lacking synaptic organizing proteins such as 
neurexin-1α, Shank2- or Shank328–30. In addition, both Shank2- and Shank3-deficient mice 
display altered expression of synaptic proteins, reduced density and abnormal shape of 
dendritic spines. Second, excitation-inhibition imbalance is implicated in a range of 
monogenic ASD models including homozygous deletion of CNTNAP2 in mice, a gene 
important for clustering potassium channels and neurodevelopment; mice heterozygous for 
SynGAP, a gene involved in dendritic spine development; and mice with the ASD-associated 
R451C missense mutation in synaptic organizing gene Neuroligin-3.31–33. Third, studies in 
MeCP2, a gene transcription regulator, knockout mice suggest that distinct cellular entities, 
particularly astroglia34 and microglia (35; but also see36) may play a significant role in the 
neurobiology of Rett syndrome.
Among a host of behavioral abnormalities, several of these studies reported abnormal social 
interactions and repetitive self-grooming in the mice. When investigators interpret these 
findings, a prevailing idea is that these behaviors are comparable to DSM-defined symptoms 
of ASD and causatively related to the cellular and neural circuit abnormalities observed. 
Consequently, a common view is that approaches correcting some circuit defects or the 
abnormal behaviors in animal models could directly translate to treatments in affected 
individuals.
However, this interpretation is problematic for at least three reasons. First, although the 
cellular and neurophysiological defects reported are likely to be relevant to the disorder and 
should thus be studied further, they might neither be necessary nor sufficient to cause a 
particular abnormal behavior. Thus, it is crucial to establish a causal relationship between an 
abnormal behavior and a specific cellular or neural circuit defect, the latter of which ideally 
can also be identified in human patients. For example, decades of clinical research indicated 
that cortico-striatal-thalamo-cortical circuits are abnormally active in patients with 
obsessive-compulsive disorder37,38, but only the experimental optogenetic perturbation in 
rodent models demonstrated definitively that abnormal activity of this circuit drives 
compulsive behaviors39,40.
Second, while exome sequencing analysis of de novo mutations suggest that most mutations 
associated with ASD are missense and different mutations in the same gene can either be 
loss- or gain-of-function41, animal model studies generally tend to adopt knockout 
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approaches when attempting to understand disease relevance of the gene. The limitations of 
this approach are exemplified by studies showing that mice deficient for Neuroligin-3 and 
mice carrying the ASD-associated R451C knock-in mutation display different phenotypic 
and neurobiological abnormalities. Unlike Neuroligin-3 deficient mice, mice harboring 
R451C human mutation express residual amounts of mutant protein that may result in an 
unexpected gain-of-function33,42. Thus, inferences made from an animal model carrying a 
certain mutation may only be valid for that specific mutation or a similar set of mutations. A 
possible strategy is to exclusively model patient-specific mutations in animals using knock-
in approaches. Admittedly, studying the entirety of mutations found in affected individuals is 
currently unpractical even in rodents, yet screening for loss- or gain-of-function in cell 
culture and in simple animal models like the zebrafish may help group mutations by their 
possible mechanism of action.
The third challenge to linking mutations with circuit dysfunctions causing behaviors is that 
mouse and human behaviors as well as the circuits underlying these behaviors are not 
always directly comparable. When attempting to align clinical and preclinical findings, 
investigators should bear two things in mind. One, DSM-5 and other symptom 
classifications are designed to provide a common framework for clinical purposes in the 
absence of mechanistic understanding and disease-relevant biomarkers. This clinical 
framework cannot be used to directly guide the common preclinical framework, which 
primarily concerns neurobiological measures and molecular signatures. Thus, a specific 
mouse behavior should not be regarded as an equivalent to a human symptom, but 
interpreted as a readout that can be used to study the underlying neurobiological defects. In 
addition, despite the fact that mice and humans have homologous brain regions and complex 
behavioral repertoires, there may be significant divergence of neural circuitry, or even 
repurposing of existing circuits, caused by the unique evolutionary pressures on mice and 
humans. Specifically, unlike the similar evolutionary history and role of cortico-striatal-
thalamo-cortical circuitry in repetitive behavior in humans, non-human primates and 
rodents37–40,43,44, neural circuits that underlie rodent social behavior and primate social 
behavior may be vastly different, given their different evolutionary histories45.
In contrast to these behavioral differences and the function of evolutionarily more recent 
neural circuits which may diverge widely between rodents and primates, synaptic genes and 
their cellular functions are largely conserved throughout vertebrate and invertebrate 
evolution46. Thus, shifting emphasis from behavioral resemblance to studying evolutionarily 
conserved circuits and neurophysiological correlates of disease-specific mutations may 
significantly increase the translatability of preclinical studies. Among many models that 
have been developed recently, the monogenic models listed in Table 1 revealed several 
cellular and circuit abnormalities that are implicated in pathophysiology of psychiatric 
disease. In addition, various abnormal behaviors have been demonstrated in these mice. It 
should be noted that the cellular and molecular abnormalities are relevant to the mutation, 
but not necessarily causative for the abnormal behavior observed.
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Tackling polygenicity
The aforementioned monogenic models have significantly enhanced our understanding of 
underlying molecular, cellular and circuitry defects caused by these particular mutations. 
That being said, a major limitation with this approach is that we can only generate 
monogenic models for highly penetrant variants (e.g. Shank3, MeCP2). Based on current 
knowledge, such highly penetrant variants may account for only 5–15% of cases in ASD, 
whereas the majority of patients with psychiatric disease may harbor many variants of small 
effect size that cumulatively confer genetic risk to disease41,47–49. In addition, the majority 
of variants may localize to non-coding regions, which are difficult to study due to limited 
understanding of the function of these regions and poor sequence conservation between 
species. For schizophrenia, the generation of animal models that reflect disease etiology is 
impeded by the lack of highly penetrant variants that are replicated across more than just a 
few families47. In a few cases, such as deletions of Neurexin-1, a gene important for synapse 
development, mutations are highly penetrant and found in many patients, but clinically they 
manifest as many different disorders50,51. Thus, until further genetic and neurobiological 
studies reveal more information about these complex diseases, relatively simple genetic 
animal models are not within reach and alternative approaches are required to elucidate the 
fundamental biology of polygenic diseases.
iPSCs and polygeneticity
Currently, a promising approach to understanding polygenicity is to use patient-derived 
induced pluripotent stem cells (iPSC) - the strength of this approach is that these cells have 
the same complex genetics as the affected indiviudal, which is crucial for dissecting the 
pathophysiology of polygenic diseases. While most initial human iPSC studies focused on 
monogenetic disorders52–55, a few new studies are starting to reveal interesting cellular 
phenotypes in iPSC-derived neurons from patients of unknown genetic causes56,57. 
However, despite great promises, there are currently still several obstacles hampering 
significant advances in modeling psychiatric diseases using these cells. Briefly, the main 
hurdles when using neurons differentiated from human iPSC are line to line variability due 
to culture conditions and genetic backgrounds; the neurons differentiated from iPSCs are 
less mature than adult human neurons with few spines, a subcellular compartment strongly 
implicated in pathophysiology of psychiatric disorders; lack of robust ways to differentiate 
the vast variety of neuronal cell types; and neurons differentiated from iPSC do not form 
complex neural circuits, which substantially constrains the complexity of neurophysiological 
endophenotypes that can be studied and related to relevant behavioral endophenotypes.
To overcome these hurdles, more sophisticated approaches for using iPSC-derived neurons 
have been explored. One of them is the development of organoids for studying local 
circuits58,59. These organoids contain cortical layer-like structures and multiple neuronal cell 
types60 and have been used to study neural developmental defects in ASD61. Another 
approach is to generate chimeric models by injecting fluorescently labeled human iPSC into 
the developing brain of rodents or primates. If the fluorescently labeled iPSCs becomes an 
integral part of the developing and migrating neuronal progenitor pool, iPSC-derived 
neurons may become incorporated into functional circuits62,63. In an experimental setting, 
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fundamental biological processes can then be investigated in patient iPSC and control iPSC 
in the same animal with different fluorescent labeling, which intriguingly may also solve in 
vitro differentiation issues and the problem of neuronal maturation including dendritic spine 
formation. The developing brain, being the natural environment for differentiating neurons, 
endogenously provides all the factors necessary for differentiation and the physiological 
formation of mature spines. Although the study of iPSC-derived neurons is still in early 
stages, further developing these approaches could be critical for studying polygenic 
disorders.
GWASs and polygenecity
In addition to patient iPS cells, we might also use GWAS data to gain insights on 
polygenicity of psychiatric disorders. GWAS studies reveal common genomic loci and 
alleles that convey increased risks for the disease rather than identifying large effect rare 
mutations20. Risk alleles and other genetic or non-genetic (such as environmental) factors 
may converge on altering functions of the same disease-relevant pathway and circuit and 
thus collectively push it towards pathological states. Therefore, highly significant GWAS 
results allow us, with confidence, to identify genes that function in disease-relevant 
pathways and circuits. With the increasing numbers of risk alleles identified by GWAS and 
large numbers of rare variants discovered in whole exome and whole genome sequencing, it 
is conceivable that systematic analysis of risk gene functions with cell type-specificity in 
simpler model systems may allow us to subgroup risk genes into converging pathways based 
on their effects on cellular and circuits function. These pathway-specific gene list can in turn 
help bioinformatic analysis of large scale genetic data to identify potential polygenic 
combinations and guide experimental validation.
Primate models for studying higher brain function and dysfunction
The ability to genetically modify the mouse genome has revolutionized biomedical research 
including neuroscience. Mouse and rat models have been and will likely continue to be the 
main mammalian models for studying brain function and dysfunction. However, mice and 
humans are separated by 80 million years of evolution, which led to significant divergence in 
the structure and function of the brain, such as in the prefrontal cortex, which is one of the 
largest and most developed portions of the human brain whereas rodents have only a 
rudimentary prefrontal cortex and lack some of the counterparts of the primate prefrontal 
cortical regions (Figure 2). Thus mice do not exhibit the same complexity in cognitive 
functions that are mediated by these regions in primates on the basis of current 
knowledge64,65. There are also many unique functional circuits and related behaviors that 
are frequently affected in human psychiatric disorders and almost impossible to study in 
rodents such as face recognition, eye gazing and vocalization, all of which play important 
roles in social cognition and social communication66–68.These differences have led to the 
exploration of primate models for research of higher brain function and psychiatric 
disorders69.
Although potential advantages of primate models will be discussed below, as for any other 
animal model in biomedical research, it remains imperative to address any scientific 
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questions in the phylogenetically lowest adequate species possible and to minimize adverse 
experience of the animal. With regard to the use of primate models, there are additional 
ethical concerns, and these experiments should only be carried out if deemed absolutely 
necessary.
One issue relevant to the use of primate models more generally, even beyond neuroscience 
research, has been that until recently, precise genetic manipulations in mammals have been 
limited to rodents. The development of highly efficient CRISPR genome-editing technology 
has made it feasible to directly manipulate the genome in zygotes70–72, thus expanding 
genetic manipulations to many species including primates73. A second issue is reproduction: 
although macaque monkeys are the most commonly used non-human primates in 
neuroscience research, they are less desirable as a routine genetic model due to their long 
generation time and slow reproduction. Macaque monkeys live up to 30 and 40 years in 
captivity, reach sexual maturity at the age of 3–4 years and give birth once a year to a single 
offspring. Thus, establishing a sizable transgenic colony means years of waiting.
Among primates, an attractive species to generate genetic models for the investigation of 
psychiatric disorders is the common marmoset74. The common marmoset is a small (300–
400g) New World monkey that is not evolutionarily as close to humans as the Old World 
monkeys such as macaques. However, from the practical point of generating transgenic 
models, the marmoset has several advantages75. First and most importantly, marmosets 
reach sexual maturity around 12–15 months and thus breeding is much faster than with 
macaques. Furthermore, marmosets give birth twice a year, usually with non-identical twins 
from each birth. This rapid reproduction cycle is an advantage for generating transgenic 
animals. Similarly, the relatively rapid maturation of marmosets compared to macaques is an 
advantage for longitudinal studies of postnatal development and for studying late onset brain 
disorders. With regard to behavioral characteristics, marmosets are highly social, with strong 
family structures and complex vocal communication, and thus could be a promising model 
for studying social cognition and communication, behaviors affected in ASD and 
schizophrenia. Like macaques but unlike rodents, marmosets have a well-developed 
prefrontal cortex, a region critical for the cognitive functions that are impaired in many 
psychiatric disorders65.
However, primate models do have their limitations. Although primates are evolutionarily 
closer to humans than rodents, they are by no means perfect models for the human brain and 
human behavior. Most notably, primates do not speak but communicate in vocal calls that 
are rudimentary compared with human language. Second, while primates have a well-
developed prefrontal cortex, transcriptomic analysis has revealed significant differences in 
cortical gene transcript expression patterns and complexity between primates and humans76. 
Thus, primates may be better models for human brains only in some aspects. At this early 
stage, neither failed nor successful translational attempts based on primate models have been 
made, which would be necessary to assess the value of primate models for human disease. 
Third, unlike for research in rodent models, extensive tools for detailed circuit interrogation 
and functional manipulation are not yet readily available. Fourth, studying genetic variants 
that may be related to more variable, subtle changes and thus require larger cohorts to 
warrant robust hypothesis testing is unpractical in primates. These scientific limitations, 
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together with the ethical considerations mentioned above and the high cost of maintaining 
primate colonies, call for caution and clear reasoning regarding scientific necessity when 
considering primate models.
The pursuit of translatability: aligning preclinical to clinical research
The shortcomings associated with the assessment of animal models based on face, construct 
and predictive validity in the past as outlined above and the low translatability of findings 
from animal models to human patients indicate that the validity evaluation and study of 
animal models should fundamentally change64. Specifically, NIMH recently launched the 
Research Domain Criteria (RDoC) initiative that spearheads the initiative to extend clinical 
research beyond the mere assessment of subjective symptoms and observable signs to an 
assessment that is also based on objective genetic and neurobiological measures65. We 
suggest that preclinical animal research should follow this example by de-emphasizing face 
and predictive validity and focusing on neurobiological validity, encompassing 
neuropathology, molecular pathways, and cellular and circuit mechanisms66. Admittedly, 
assessing neurobiological validity in an animal model is still difficult due to the lack of 
knowledge regarding the precise nature of neurophysiological abnormalities in human 
patients. However, it is worth noting that with advanced neuroimaging, 
electroencephalography (EEG) and magnetencephalography (MEG) recording, and 
transcranial magnetic stimulation (TMS) approaches, ongoing clinical research has great 
potential to build a framework of disease correlates in the near future; and we already know 
several neurophysiological abnormalities in patients, which can guide mechanistic studies in 
animal models and be considered for validity assessment of an animal model (reverse 
translation).
This is exemplified by schizophrenia research, where reported neurophysiological alterations 
in human patients include abnormalities in local gamma and sleep spindle activity67–70, 
long-range functional connectivity71,72, impaired long-range structural connectivity (73 and 
references therein), and morphological changes, such as decreased dendritic spine density 
and cortical thinning74–76.
How are these neurophysiological phenomena studied in human patients? Functionally, local 
oscillatory cortical activity arises from synchronous activation of large neuronal ensembles. 
This is measured with extra-cranial EEG, electrocorticography (ECoG) or MEG as steady-
state evoked potentials (SSEP) or as strength of gamma-oscillation in testing paradigms 
engaging the auditory or visual sensory systems69,70,77,78. Similarly, one can use covariance 
analysis of the fMRI BOLD response from two regions (functional magnetic resonance 
imaging, blood oxygen level dependent) to study long-range functional connectivity of 
neuronal ensembles in distant brain regions.71,72. The morphological framework for such 
oscillations is laid by the hard-wiring and structural connectivity of brain regions. Here, 
diffusion tensor imaging (DTI) allows the visualization and quantitative assessment of long-
range projections on the macroscopic scale. Lastly, both dendritic spine counting upon 
Golgi-impregnation in postmortem tissues and structural MRI in patients can be carried out 
to study structural alterations such as atrophy or hypertrophy of certain regions.
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Can preclinical research move towards employing the same or equivalent approaches in 
animal models to study neurobiological correlates? Although such studies outlined above are 
still scarce in animal models, various examples are listed in table 2, together with a non-
exhaustive summary of both widely and rarely adopted useful methodologies for the 
elucidation of functional and morphological neurophysiological disease correlates. Using 
and developing more such methods to better align preclinical research with clinical work 
requires basic scientists to closely collaborate with clinical scientists to learn disease 
relevant knowledge.
Regarding the investigation of functional properties, two studies are of particular interest. 
Using paired recording of spikes and field potentials with multiple recording electrodes in a 
model for deletion of schizophrenia-associated 22q11.2 region, one study revealed impaired 
fronto-temporal synchrony as a neurophysiological abnormality79, while the other study 
adopted ECoG measurements in mice lacking the schizophrenia-associated 15q13.3 
homologue to reveal impairments of SSEP and a reduction of evoked gamma power80. In 
terms of structural changes that correlate with disease, a study investigating gross anatomy 
of the brain found an increased caudate volume in a mouse model for ASD29, which is 
consistent with findings in human patients81. Macroscopic structural mapping of fiber tracts 
using diffusion tensor imaging (DTI) is not yet routinely performed in common laboratory 
animals. With improved resolution down to 50 µm3 for ex vivo and 200 µm3 for in vivo 
interrogations, this technique can be used in animal models such as the common 
marmoset
82
. In addition, recently developed tissue-clearing techniques such as Clear Lipid-
exchanged Acrylamide-hybridized Rigid Imaging/Immunostaining/In situ hybridization-
compatible Tissue-hYdrogel, (CLARITY) for mesoscale optical investigation, which renders 
the brain transparent in its native three-dimensional state, can be used to reveal 
morphological abnormalities in animal models83. Together with classical 
electrophysiological and molecular interrogation of disease-relevant brain circuits in model 
organisms chosen based evolutionary conservation of such circuits, such as basal ganglia 
and amygdala for studying compulsions and innate fear in rodents, respectively7,84–86, these 
approaches help elucidate neurophysiological disease correlates that are likely comparable 
between humans and animal models.
With these approaches, it is conceivable that investigators will be able to make more valid 
inferences about human pathophysiology and better predictions of treatment response in 
patients, but which other opportunities can be explored to improve our understanding of 
pathophysiology? Reviewing the recently developed animal models, arguably one of the 
most striking disconnects is the fact that interrogation of neurobiological mechanisms is 
largely conducted in adult animals, while a substantial portion of psychiatric disease is 
developmental. Thus, instead of revealing developmental neurobiological abnormalities that 
are potentially causal to the abnormal neurobiology observed in the adult and still malleable 
to interventions, current studies focus on studying potentially less malleable consequences 
of such developmental abnormalities at the adult stage. Specifically, it is conceivable that 
molecular signatures during development characterize fundamental neurobiological wiring 
and circuit maturation steps with different potentials regarding reversibility, such that some 
circuit abnormalities are reversible in adulthood, while others may only be sensitive to 
treatment in early development32. Regarding future preclinical research, one critical 
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advantage of the technologies outlined above is that they permit longitudinal studies on 
functional and morphological abnormalities along development with potential to identify 
critical plasticity periods or neurophysiological and molecular signatures of prodromal 
stages87. In an experimental setting, animal models offer the unique opportunity to 
invasively probe early interventions targeted at linked candidate pathways or circuits by 
utilizing drug treatments or deep brain stimulation and transcranial magnetic stimulation, 
respectively88, while also being able to study these effects on defined neurobiological 
abnormalities at various stages along development.
Despite the notion that focusing on neurophysiological defects is critical for better 
translatability of studies using animal models, studying behavior will not become irrelevant, 
since behavior is an important organism-level readout of circuit dysfunction and correction. 
Rather, bearing in mind the limitation that a change in animal behavior upon experimental 
treatment is by itself insufficient as readout for successful treatment response, future 
preclinical work may use it as one of many readouts for the correction of the mechanistically 
understood neurobiological abnormalities.
The path forward: convergent science
Attempts to develop effective treatments for psychiatric diseases with the help of animal 
models were largely unsuccessful in the past decades. In brief, the main reasons for this 
disconnect are that heterogeneous patient populations were treated as homogeneous units, 
the fundamental underlying biological mechanisms were and mostly remain unknown, and 
the readouts used for treatment response in preclinical research were poor predictors of 
treatment response in the clinical setting.
Psychiatric diseases stand in contrast to other diseases, such as cancer, where preclinical 
research significantly advanced our understanding of the underlying mechanisms and 
revealed many robust biomarkers. For some types of cancer, mechanistic understanding and 
the availability of robust biomarkers facilitated the evolution of therapy from unspecific 
cytotoxic drugs to the highly effective compounds that target cancer subtype-specific 
pathways and thus personalized medicine89,90.
To introduce a similar process to psychiatric disease research, we envision a path forward 
that leads to the convergence of clinical research, preclinical neuroscience, and drug 
discovery (Figure 3). This path comprises of four key steps. First, driven by the new NIMH 
Research Domain Criteria (RDoC) program, groups of highly heterogeneous patients 
diagnosed with a given disorder are deconstructed, parsed, and categorized into more 
homogeneous clusters on the basis of genetics, observable signs and neurobiological 
abnormalities revealed by imaging and neurophysiology65,91. Second, mirroring the 
principles of RDoC, preclinical neuroscience uses genetic-based animal models and patient 
iPSC models to identify, understand and validate the relevance and underlying mechanisms 
of neurobiological abnormalities found in patients. Third, preclinical researchers develop 
treatment strategies targeting distinct/relevant neurobiological abnormalities with specific 
compounds and other interventions, such as deep brain stimulation or transcranial magnetic 
stimulation, while utilizing animal and cellular models to iteratively validate and refine these 
Kaiser and Feng Page 12
Nat Med. Author manuscript; available in PMC 2016 May 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
treatment strategies. In this step, it is critical to identify comparable abnormalities in 
conserved domains between humans and animal models. Finally, treatment domains and 
more homogeneous clusters of patients are formed based on shared measureable 
abnormalities and biomarkers that are conserved and comparable between animal/cellular 
models and human patients. In clinical trials, these treatment groups receive the appropriate 
treatment developed based on shared mechanisms, some of which could potentially have 
been pre-validated in patient iPSC-derived neurons and thus significantly increasing the 
chances of treatment success.
Similar to cancer research, this convergent approach will help close the gap between clinical 
and preclinical research, establish a fundamental understanding of pathophysiology, and 
bring more precise and effective treatments to patients. Although this will unlikely result in a 
singular treatment strategy for all patients with the same DSM diagnosis, several specific 
mechanism-based treatments can be used in combination, potentially even cutting across 
similar disorders, to match the patients’ specific needs.
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Figure 1. Clinical approval of CNS-drugs
A) The clinical approval success rates for CNS drugs fall far below drugs for non-CNS 
disorders between 1995 and 2006. Except for a period of increased approvals of so-called 
me-too-drugs, the approval rates were consistently low with about 5 in a 100 compounds 
receiving approval.
B) In contrast to compounds for CNS disorders, the share of FDA approval rate for 
antineoplastic drugs increased substantially between 1995 and 2006, since therapy evolved 
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from unspecific cytotoxic compounds to highly cancer-specific compounds. Source: Tufts 
Center for the Study of Drug Development92.
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Figure 2. The change in cortical fields and medial frontal cortex architecture since the last 
common ancestor of rodents and humans
Bottom: The common ancestor of mice, monkeys, and humans is likely to have displayed 
extended somatosensory areas, but small parietal fields. On a gross scale, similar 
organization can be found in the rodent brain, whereas humans and monkeys, most probably 
driven by their visual specialization, have profoundly expanded parietal fields and reduced 
somatosensory areas. Considering brain architecture revealed by histological staining, the 
absence of a well-developed granular homotypical cortex in rodents is striking. Although 
rodents may possess functionally analogous regions, distinct cell-type composition and 
computations in these regions, which are implicated in psychiatric disease in patients, may 
be unique to primates. Illustrations are schematic and not drawn to scale. A1: primary 
auditory cortex, AC1 and AC2: anterior cingulate cortex area 1 and 2, Fr2: frontal area 2, IL: 
infralimbic cortex, MO: medial orbital cortex, OB: olfactory bulb, PL: prelimbic cortex, 
PPC: posterior parietal cortex, S1 and 2: primary and secondary somatosensory cortex, V1 
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and V2: primary and secondary visual cortex, VO: ventro orbital cortex. Numbers 
correspond to Brodmann areas. Adapted and modified from93–95.
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Figure 3. The path forward: convergence of clinical and preclinical research
In this hypothetic example of the way forward in treatment development, a heterogeneous 
group of ASD patients is sub-grouped on the basis of genetics and comprehensive Research 
Domain Criteria (RDoC). The genetic information obtained in this process also informs 
preclinical neuroscience and enables the generation of animal models that are similar to the 
patient in their biological basis. Mirroring the patient RDoC, the same neurophysiological 
abnormalities are identified, understood and tested in terms of their relevance to disease. 
Shown schematically here, testing causation through invasive perturbation in animal models 
mirrors the importance where correlative genetic observation stands in human patients. Next, 
these valid models are used for invasive and iterative treatment development. Finally, 
homogeneous treatment domains are formed based on comparable abnormalities in 
conserved domains and patients within these clusters receive the appropriate treatment for 
their specific defect, e.g. patient with neurophysiological abnormality A receives the 
treatment that has been developed for the corresponding defect in animal models. It is also 
conceivable that another group of patients displays neurobiological abnormalities A and B 
and thus receives a combinatorial treatment of A and B.
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Table 1
Recently developed human genetics-based animal models point towards synaptic mechanisms
Genetic mouse model Cellular and neurophysiological abnormality Behavioral abnormality
Shank2 knockout96,97 Reduced hippocampal glutamatergic neurotransmission, 
reduced
spine density, increased glutamate receptor expression96 or
reduced NMDAR function97
Excessive grooming, increased
social interaction, abnormal vocalizations
Shank3 knockout-Ankyrin 
repeat98–100
Shank3 knockout-PDZ domain29
Shank3 knockout-Exon 21101
Shank3 overexpression102
Impaired hippocampal synaptic transmission and LTP, 
reduced
PSD proteins, reduced activity-dependent AMAPR98–100
Reduced cortico-striatal neurotransmission, reduced PSD 
and
PSD proteins, reduced spine density, increased dendritic 
length,
striatal hypertrophy29
Hippocampal synaptic defects, increased mGluR5 in 
PSD101.
Abnormal EEG, decreased mIPSC frequency and increased
sEPSC in the hippocampus, increased spine density, 
increased
excitatory synaptic markers and reduced inhibitory 
markers102.
Abnormal social behaviors, 
communication
repetitive behaviors and learning
Excessive grooming, impaired social
increased anxiety29
Spatial learning and memory defects,
deficits, hypersensitivity to heat,
Increased locomotor activity, 
hypersensitive
amphetamine, abnormal circadian
CATNAP2 knockout31 Abnormal EEG, cortical neuronal migration abnormalities,
reduced cortical neuronal synchrony, reduced number of
interneurons in striatum and cortex
Excessive grooming, epileptic
behavior, abnormal vocalizations
Neuroligin-3 knockout and R451C 
knock-in33
Increased inhibitory synaptic transmission in 
somatosensory
cortex, increased expression of inhibitory neuron markers 
in
hippocampus and somatosensory cortex
Impaired social interaction, enhanced
SynGAP1 knockout of one allele32 Elevated excitatory synaptic transmission during 
development,
premature spine maturation, abnormal dendritic spine size 
and
shape, abnormal E/I balance in the hippocampus
Seizures, learning deficit, hyperactivity
MeCP2 knockout103; MeCP2 
microglia rescue34;
MeCP2 astrocyte rescue104
Reduced neuronal cell size, reduced number of dendritic
branches, microglia phagocytic activity
Decreased body weight, decreased
shortened lifespan
Neurexin-1α knockout30 Reduced excitatory synaptic transmission in the 
hippocampus
Decreased prepulse-inhibition,
impaired nest-building, improved
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Table 2
Preclinical and clinical research converges through use of comparable approaches in conserved domains.
Neurophysiological
domain
Technology Examples for findings in 
human
patients
Examples for 
application in
animal models
Highlights
Functional connectivity:
Local synchrony
Wireless 
Electroencephalography
(EEG), Electrocorticography 
(ECoG),
Magnetencephalography 
(MEG)
Reduced gamma power 
and abnormal
sleep spindles in 
schizophrenia67–70
Auditory processing 
deficits in
15q13.3 deletion 
heterozygous mice
80
 and abnormal spike 
discharges
after seizure onset in 
CNTNAP2
mutant mice31
Longitudinal study
Possible in freely
Functional connectivity:
Long-range synchrony
Functional Magnet Resonance
Imaging (fMRI), Positron 
Emission
Tomography (PET), paired
electrophysiology in two 
regions
Abnormal functional 
connectivity in
schizophrenia71,72
Impaired fronto-
parietal synchrony
in 22q11.2 deletion 
schizophrenia
model79
fMRI: Repeated non
imaging/longitudinal
unbiased whole-brain
equivalent readout
Structural connectivity Diffusion Tensor Imaging 
(DTI),
CLARITY, electron 
microscopy
Abnormal connectivity in 
schizophrenia
73
No defects in NLGN-3 
knockin mice
with DTI studies105
DTI: Longitudinal
CLARITY: probing
native three-
dimensional
Anatomy Three-dimensional magnet 
resonance
imaging (MRI)
Golgi-impregnation
Increased caudate volume 
in ASD
patients81
Reduced spine density in 
schizophrenia
Increased caudate 
volume and
reduced spine number 
in Shank3-
deficient mice29
MRI: Longitudinal
Equivalent readout
models
Gene and protein
expression,
transcriptional
dynamics, single cell
transcriptome
In situ hybridization (ISH),
Immunohistochemistry, mass
spectrometry, bilsulfite 
sequencing,
ChIP, isoform-specific RNA 
seq
Reduced parvalbumin 
expression in
prefrontal cortex in 
schizophrenia post-
mortem tissue106, Mid-
fetal
transcriptional networks 
in ASD87
Abnormal synaptic 
protein
expression in Shank2- 
and Shank3-
deficient mice29,96
Reduced parvalbumin-
positive
interneurons numbers 
in CNTNAP2
mutant mice31
High sensitivity
Potential to identify
developmental periods
Identification of 
converging
pathways
Neuronal transmission
and synaptic plasticity
Ex vivo and in vivo 
electrophysiology
(sharp electrode, stereotrodes,
tetrodes, large electrode arrays)
Impaired LTP and LTD in
schizophrenia107,108
Abnormal synaptic 
transmission in
Shank2- and Shank2-
deficient mice
28
,
29
Unprecedented 
temporal
robustness and 
molecular
with pharmacology
This non-exhaustive summary lists various useful techniques that help reveal neurobiological abnormalities, which are largely conserved and 
therefore likely comparable between human patients and animal models. Note that invasive preclinical approaches have the potential to identify 
molecular signatures and pathways that may serve as treatment targets, whereas classical clinically used approaches allow for the longitudinal study 
of treatment effects while also ensuring better translatability.
Nat Med. Author manuscript; available in PMC 2016 May 31.
